IP Library Granted Patent US 9,526,772
Granted Patent B2
US 9,526,772 · App. 14/649,138 · Granted Dec 27, 2016

Ehrlichial invasin for immunization, diagnosis, and cell delivery

Inventors: Yasuko Rikihisa (Worthington, OH); Dipu Mohan-Kumar (Columbus, OH)
Assignee: Ohio State Innovation Foundation
A61K39/0233A61K39/385A61K47/4833C07K14/29G01N33/6854C07K2319/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,526,772
App. No.
14/649,138
Granted
Dec 27, 2016
Kind
B2
Abstract

Disclosed are vaccines containing one or more immunogenic polypeptides derived from an EtpE protein from an Ehrlichia sp. or nucleic acid encoding these polypeptides. Also disclosed is a method for vaccinating a subject against Ehrlichia sp. that involves administering to the subject a composition comprising any of the disclosed vaccines. Also disclosed is a method for diagnosing and/or monitoring the treatment of Ehrlichiosis in a subject that comprising assaying a biological sample (e.g., blood, serum, or plasma sample) from the subject for the presence of an antibody that specifically binds an EtpE polypeptide. Also disclosed are methods for delivering a therapeutic or diagnostic agent to a cell in a subject that involves conjugating the agent, or a delivery vehicle comprising the agent, to polypeptide containing the C-terminal domain of an EtpE protein.

Claims (8)

1. A method for delivering a therapeutic or diagnostic agent to a cell in a subject, comprising administering to the subject a composition comprising the agent, wherein the agent, or a delivery vehicle comprising the agent, is conjugated to a delivery polypeptide comprising an amino acid sequence having at least 70% identity to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or to a nucleic acid encoding the polypeptide operably linked to a promoter.

2. The method of claim 1 , wherein the composition comprises a fusion protein comprising the agent and the delivery polypeptide.

3. The method of claim 1 , wherein the composition comprises a DNA expression vector encoding a fusion protein comprising the agent and the delivery polypeptide operably linked to a promoter.

4. The method of claim 1 , wherein the composition comprises a nanoparticle, microparticle, or microsphere encapsulating the agent, wherein the delivery polypeptide is positioned on the surface of the nanoparticle, microparticle, or microspheres.

5. The method of claim 4 , wherein the microsphere comprises (lactide-co-glycoid or polyanhydrides.

6. The method of claim 1 , wherein the composition comprises a biodegradable polymers conjugated to the delivery polypeptide.

7. The method of claim 1 , wherein the cell comprises a monocyte.

8. The method of claim 1 , wherein the cell comprises a heart or skeletal muscle cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: RIKIHISA, YASUKO; MOHAN-KUMAR, DIPU
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 035768/0723 →
Continuity (3)
Provisional Application 61732491 · Dec 3, 2012
Provisional Application 61810039 · Apr 9, 2013
Related Publication 20150313983A1 · Nov 5, 2015